Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on developing treatments for central nervous system (CNS) movement disorders and fluency disorders, will present an abstract — “Ecopipam in Children and Adolescents with Tourette Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2b Study"— at the American Academy of Neurology’s (AAN) Annual Meeting.
Findings show investigational drug reduces tics by 30%; Data presentation April 5 CHICAGO, March 31, 2022 /PRNewswire/ -- Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on developing treatments for central nervous system (CNS) movement disorders and fluency disorders, will present an abstract — “Ecopipam in Children and Adolescents with Tourette Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2b Study"— at the American Academy of Neurology’s (AAN) Annual Meeting, April 2-7, in Seattle. Findings show investigational drug reduces tics by 30% in pediatric patients with Tourette Syndrome. Positive topline results from Emalex’s Phase 2b clinical study (D1AMOND Study) evaluating the efficacy and safety of ecopipam (EBS-101), an investigational, first-in-class, dopamine-1 (D1) receptor antagonist, for the treatment of pediatric patients with Tourette Syndrome, were announced in late 2021. The results were statistically significant and clinically meaningful on the primary and multiple secondary efficacy endpoints. In the study the drug was also well tolerated by study participants. “The robust results of our ecopipam study are very encouraging, giving us momentum to continue our important work towards a safe and effective therapy for pediatric patients living with Tourette Syndrome,” said Atul R. Mahableshwarkar M.D., Chief Medical Officer, Psychiatry, and Senior Vice President of Drug Development. “I am eager to publicly share full data of our study knowing we are one step closer to finding relief for people living with this disorder.” Abstract co-author Dr. Mahableshwarkar will present study findings on Tuesday, April 5 at 1:36 p.m. CT (11:36 a.m. PT) in Ballroom 6E at the Washington State Convention Center. About Ecopipam Ecopipam has been shown to be generally well tolerated in clinical trials conducted to date and has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration for the treatment of patients with TS. Adverse events affecting primarily the central nervous system [CNS] (e.g., sedation, insomnia, psychiatric changes) and the gastrointestinal system (e.g., nausea and vomiting) are the most frequently reported side effects. About Emalex Biosciences About Paragon Biosciences Media Contact:
SOURCE Emalex Biosciences, Inc. |